Gynecologic Cancers

Immune-related adverse events

Questions discussed in this category

What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?

1 Answer available

When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?

How do you decide if it may be safe to continue immunotherapy?

1 Answer available

How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?

3 Answers available

Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?

1 Answer available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

Papers discussed in this category

Cancer management and research, 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Lancet Oncol., 2020 Mar 03

Risk of COVID-19 for patients with cancer.

Lancet, 2020 Feb 07

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Ann. Rheum. Dis., 2019 Sep 20

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

J Immunother Cancer, 2021 Feb

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

J Natl Compr Canc Netw,

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Ann Oncol,

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Immunother Cancer,

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer,

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

Arthritis Rheumatol, 2021 Apr 01

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Related Topics in Gynecologic Cancers